Immunodeficiency CRISPR Knockout Cell Models for Drug Discovery

Primary immunodeficiency diseases (PIDs) encompass over 450 genetic disorders affecting the immune system, with an estimated global prevalence of 1 in 1,200 live births (WHO, 2023). Severe combined immunodeficiency (SCID) occurs in approximately 1 in 58,000 births and is fatal within the first year without treatment. The 5-year survival rate for PID patients with hematopoietic stem cell transplantation is 70-90% depending on the subtype (NCI, 2023). Key risk factors include consanguinity, family history, and specific genetic mutations. The clinical impact includes recurrent infections, autoimmunity, and increased cancer risk, particularly lymphoma.

Immunodeficiency is ideal for mechanistic studies due to its well-defined genetic basis and the availability of public datasets such as the IUIS PID classification and ClinVar. Subtypes like SCID, common variable immunodeficiency (CVID), and hyper-IgM syndrome provide clear genotype-phenotype correlations. Open questions include the role of hypomorphic mutations, the impact of modifier genes, and the development of targeted therapies. Gene-edited cell models enable precise dissection of immune signaling pathways and the validation of novel therapeutic targets.

Immunodeficiency arises from defects in key immune pathways:

• • V(D)J Recombination Pathway:

1. RAG1/RAG2 initiate DNA cleavage at recombination signal sequences.

2. Artemis (DCLRE1C) processes hairpin ends.

3. DNA-PKcs and XRCC4 ligate coding ends.

• • Mutations in RAG1, RAG2, or DCLRE1C cause SCID or Omenn syndrome.
• • Cytokine Receptor Signaling (JAK-STAT):

1. Cytokine binding to common gamma chain (IL2RG) activates JAK3.

2. JAK3 phosphorylates STAT5, which translocates to the nucleus.

3. STAT5 drives expression of genes for T and NK cell development.

• • Mutations in IL2RG or JAK3 cause X-linked or autosomal recessive SCID.
• • Adenosine Deaminase (ADA) Pathway:

1. ADA converts adenosine to inosine.

2. ADA deficiency leads to accumulation of deoxyadenosine, toxic to lymphocytes.

3. Results in SCID with severe lymphopenia.

• • ADA deficiency accounts for 15% of SCID cases.

Data from TCGA, COSMIC, and ClinVar (2023).

• • JAK-STAT Pathway: Key nodes include IL2RG, JAK3, STAT5. Loss of function leads to absent T and NK cells.
• • V(D)J Recombination: Key nodes include RAG1, RAG2, DCLRE1C, DNA-PKcs. Defects cause arrested lymphocyte development.
• • Purine Metabolism: Key nodes include ADA, PNP. Accumulation of deoxyadenosine or deoxyguanosine induces lymphocyte apoptosis.
• • TCR Signaling: Key nodes include CD3 subunits, ZAP70, LCK. Mutations cause combined immunodeficiency with defective T cell activation.

Organoids derived from patient iPSCs or hematopoietic stem cells offer 3D architecture and multi-lineage differentiation, enabling study of immune cell development and interaction.

• • PDX Models: Patient-derived xenografts in NSG mice reconstitute human immune system, allowing study of PID in vivo.
• • GEMM Models: RAG1-/- and IL2RG-/- mice recapitulate SCID phenotypes.
• • Induced Models: CRISPR-mediated knockout of ADA in mice causes severe lymphopenia.

CRISPR isogenic lines provide precise genetic control for studying immunodeficiency. For example, TP53-/- or KRAS G12D models are not directly relevant, but IL2RG knockout in Jurkat cells or RAG1 knockout in HCT116 cells enable functional studies. Commercially available, sequence-verified models accelerate research by eliminating off-target effects and ensuring reproducibility. These models are used for drug screening, pathway analysis, and target validation without the need for primary patient samples.

Knockout of IL2RG in Jurkat cells confirms its role in JAK-STAT signaling and T cell proliferation. Knock-in of RAG1 mutations in HCT116 cells validates the impact on V(D)J recombination efficiency. These models allow systematic mapping of genotype-phenotype correlations.

Isogenic pairs (e.g., ADA-/- vs. ADA+/+ in K562 cells) enable screening for compounds that rescue enzyme activity. Resistance modeling: JAK3 knockout cells can be used to test JAK inhibitor specificity and identify alternative signaling pathways.

CRISPR synthetic lethality screens in immunodeficiency backgrounds identify genes that become essential when immune pathways are compromised. For example, in RAG1-/- cells, screening for DNA repair inhibitors reveals potential therapeutic targets.